We reported that dexamethasone treatment of rabbits causes a reduction in renal vasoconstrictor responses to prostaglandin F^ and U46619, an agonist at the thromboxane-endoperoxide receptor, but not to phenylephrine. The purpose of this study was to examine if dexamethasone treatment can affect the renal vasodilatory responses to prostacydin (PGIi) and prostaglandin Ej (PGE2) in isolated Krebs-perfused kidneys constricted with phenylephrine. In kidneys from dexamethasone-treated rabbits, the vasodilatory response to PGI 2 was reduced by 57%, whereas that to PGE^ was converted to a vasoconstrictor response. This effect of dexamethasone appears to be specific in that the renal vasodilatory responses to forskolin and to sodium 
C onsistent with a role for glucocorticoids in
the regulation of vascular functions, glucocorticoids have been shown to bind to specific receptors in blood vessels 1 and to affect vascular reactivity 2 * 3 as well as systemic and renal hemodynamics. 4 For example, glucocorticoids have been shown either to increase or to decrease blood pressure, 4 -5 to increase renal blood flow, 6 and to reduce vascular smooth muscle contractile responses to prostaglandin (PG) F^ and U46619, a synthetic agonist for the thromboxane A 2 and PG endoperoxide receptor.
effect of PGF^ and U46619 in the isolated kidney perfused with Krebs-bicarbonate buffer. 7 Because the glucocorticoid did not interfere with the vasoconstrictor response to phenylephrine, its inhibitory influence on vascular responsiveness to pressor eicosanoids appears to be specific. Yet the possibility that dexamethasone also affects the renal vascular actions of vasodilatory eicosanoids cannot be excluded. Therefore, the present study was designed to investigate the effects of dexamethasone treatment on the expression of renal vasodilatory responses to PGE2, PGI 2 , and arachidonic acid in the isolated perfused rabbit kidney.
Methods

Animals
Male New Zealand white rabbits (2.5-3.0 kg) were treated for 6 consecutive days with dairy subcutaneous injections of dexamethasone 21-acetate (2.5 mg/kg) suspended in sesame oil. Control rabbits received injections (0.5 ml) of sesame oil Supplement I Hypertension Vol 15, No 2, February 1990 only. On the sixth day of treatment, a control and a dexamethasone-treated rabbit were anesthetized by intramuscular injection of 50 mg/kg ketamine HC1 (Ketaset, Aveco Co., Fort Dodge, Iowa) and 8 mg/kg xylazine (Rompun, Haver Mobay Corp., Shawnee, Kansas), and the left kidneys were isolated and perfused, in parallel.
Isolated Perfused Kidney
After anesthesia, the left kidney was exposed, left renal artery cannulated, renal vein and ureter cut, and the kidney freely suspended in a waterjacketed chamber maintained at 37° C. Kidneys from vehicle-and dexamethasone-treated rabbits were perfused in parallel at a constant flow of 12 ml/min with oxygenated (95% O 2 and 5% CO 2 ) Krebs-bicarbonate buffer of the following composition (mmol/1): NaCl 118. After a 60 -minute equilibration period, the perfusion pressure was 54.2±3.7 mm Hg in the kidneys of control rabbits (n=25) and 50. ml ) to inhibit cyclooxygenase. Each injection of agonist was separated by a 15-minute interval and no more than two agonists were studied in each kidney. Because the kidneys were perfused at a constant rate, the changes in perfusion pressure are indicative of changes in renal vascular resistance.
In some experiments, examining vasodilatory responses to arachidonic acid in kidneys from control and dexamethasone-treated rabbits, the renal effluent was collected at 1-minute intervals before and up to 6 minutes after injection of a 10 fig bolus of arachidonic acid. PGE} and 6-keto-PGF la , the stable hydrolysis product of PGI 2 , were measured in the renal effluent using the second antibody, solidphase, enzyme-linked immunoassay described by Pradelles et al. 8 Cross reactivities of antisera are as previously stated. 9 
Drugs
and PGI 2 were purchased from Cayman Chemical, Ann Arbor, Michigan. PGE2 was dissolved in ethanol (1 mg/ml), and aliquots were evaporated under nitrogen and resuspended in Krebs buffer. PGI 2 was dissolved (1 mg/ml) in 50 mM Tris buffer, pH 9.0, and diluted with the same buffer on the day of the experiments. Arachidonic acid purchased from NuChek (Erysian, Minnesota) was dissolved (1 mg/ml) in 50 mM sodium carbonate, pH 7.4, and diluted with Krebs buffer. Phenylephrine, sodium nitroprusside, forskolin, and indomethacin were purchased from Sigma Chemical Co., St. Louis, Missouri. Phenylephrine and sodium nitroprusside were dissolved in distilled deionized water, and forskolin was dissolved in ethanol (all at concentrations of 1 mg/ml). Indomethacin was dissolved in 50 mM sodium carbonate (1 mg/ml).
Statistical Analysis
Results are expressed as mean±SEM. The data were analyzed by two-way analysis of variance. If differences were noted, the data were analyzed by a Duncan multiple range test. The data on arachidonic acid-induced changes in renal perfusion pressure and eicosanoid output were analyzed by a paired Student's t test. Differences in responses between control and dexamethasone-treated rabbits were determined by an unpaired Student's t test. The null hypothesis was rejected if thep value was less than 0.05. Figure 1 illustrates the changes in perfusion pressure elicited by bolus arterial injections of PGI 2 and PGE 2 in isolated perfused kidneys from vehicle-and dexamethasone-treated rabbits. PGI 2 caused a dose-dependent reduction of perfusion pressure indicative of vasodilation in kidneys from both groups of rabbits. The vasodilatory response induced by PGI 2 in kidneys from dexamethasonetreated rabbits, however, was only 40-50% of that induced by PGI 2 in kidneys from vehicle-treated rabbits. PGE^ also caused dose-dependent vasodilation in perfused kidneys from control rabbits. In perfused kidneys from rabbits treated with dexamethasone, however, the injection of PGE2 caused dose-dependent elevation of perfusion pressure, which is indicative of renal vasoconstriction. Contrasting with the effectiveness of dexamethasone in reducing PGI 2 -induced renal vasodilation, and in reversing the effect of P G^ on the renal vascularure from vasodilation to vasoconstriction, the steroid did not affect the renal vasodilatory effect of forskolin and of sodium nitroprusside, activators of adenylate cyclase, and of soluble guanylate cyclase, respectively (Figure 2) . Shown in Table 1 ments with indomethacin in the perfusate to inhibit cyclooxygenase, arachidonic acid failed to change perfusion pressure in kidneys from vehicle-treated rabbits but reduced perfusion pressure by 10.5±3.5 mm Hg in kidneys from dexamethasone-treated rabbits. In kidneys perfused in the absence of indomethacin, arachidonic acid injected closearterially increased the output of 6-keto-PGF la and PGE2 to the same extent in kidneys from vehicleand dexamethasone-treated rabbits. In kidneys perfused with indomethacin, both in vehicle-and dexamethasone-treated rabbits, the arachidonic acid induced renal output of 6-keto-PGF la and PGE2 was either supressed or greatly inhibited. 'nglmin) /ml) ; arachidonic acid bolus injection (10 fig), n, number of rabbits studied; AA, arachidonic acid; a, difference between peak values obtained after the bolus administration of AA compared with basal values; V, vehicle-treated rabbits; D, dexamethasone-treated rabbits. *p<0.05, relative to basal values. tp<0.05, relative to corresponding value in vehicle-treated rabbits.
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Discussion The present study demonstrates that treatment of rabbits with dexamethasone decreases the expression of PGI 2 -induced vasodilation in the isolated perfused kidney, and reverses the effect of PGE2 from vasodilation to vasoconstriction. These effects of dexamethasone are not attributable to nonspecific inhibition of vasodilatory mechanisms because the glucocorticoid did not inhibit the renal vasodilatory effect of forskolin and sodium nitroprusside. A priori, the dexamethasone-induced alteration in renal vascular responses to PGE2 and PGI 2 can be the result of possible actions of the steroid increasing the renal degradation of PGI 2 , enhancing the conversion of PGE2 to a metabolite with vasoconstrictor activity, or impairing the stimulus-receptor coupling of events linked to prostanoid mediated vasodilation. We cannot exclude any of these possibilities as yet. There are reports, however, that dexamethasone reduces renal 15 -PG dehydrogenase activity, an effect that would tend to increase levels of PGI 2 and PGEj. 10 Furthermore, dexamethasone does not affect the renal activity of the enzyme 9-ketoreductase, thus, not influencing the conversion of PGE^ to PGF^1 1 In our study, treatment of rabbits with dexamethasone resulted in augmentation of the renal vasodilatory effect of arachidonic acid without further enhancement in the renal output of PGE^ and 6-keto-PGF lOT a metabolite of PGI 2 . This finding is surprising because the renal vasodilatory effect of arachidonic acid is thought to be mediated by PGE2 and PGI 2 , which have an impaired ability to produce vasodilation in kidneys from dexamethasonetreated rabbits. Dexamethasone treatment of rabbits also interferes with the ability of PGF2a to produce renal vasoconstriction. 7 As the renal vasodilatory response to arachidonic acid is accompanied by an increased renal production of PGF^1 2 augmentation by dexamethasone of arachidonic acid-induced renal vasodilation might be in part related to diminished effectiveness of endogenous PGF^ to elicit vasoconstriction.
Additionally, enhancement of arachidonic acidinduced renal vasodilation in dexamethasone-treated animals might be the consequence of increases in the metabolism of arachidonic acid by noncyclooxygenase pathways. Indeed, dexamethasone has been shown to enhance the formation of nicotinamide dinucleotide phosphate (NADPH)-dependent noncyclooxygenase products of arachidonic acid by renal cortical structures, and there is evidence that some of the products are further metabolized by cyclooxygenase to metabolites with biologic activity. 13 ' 14 The possibility that metabolites of arachidonic acid by a noncyclooxygenase pathway contribute to the vasodilatory effect of the fatty acid in kidneys from dexamethasone-treated rabbits is in agreement with the observation that the vasodilatory effect is not completely eliminated by inhibition of cyclooxygenase with indomethacin. Although it can be argued that the residual vasodilatory response to arachidonic acid in kidneys from dexamethasone-treated rabbits results from the enhanced release of endothelium-derived relaxing factors, there is no evidence that dexamethasone produces such an effect. 15 This study demonstrates that dexamethasone treatment of rabbits interferes with PGI 2 -and PGE2-induced renal vasodilation while increasing the renal vasodilatory effect of arachidonic acid. The reciprocal effects of dexamethasone on the renal vascular responses to arachidonic acid and vasodilatory PGs are indicative of a previously unrecognized influence of glucocorticoids on the renal arachidonate-prostaglandin system.
